Currently the PD is responsible for developing drugs from a biological (Actimmune (interferone 1b gamma) which has been FDA approved for use in use in the following National Cancer Institute (NCI) protocols:
• 07-C-0206
• 08-C-0051, 0-C-0139
• 13-C-0016.
The purpose of this requirement is to procure the needed raw material to support the ongoing and newly approved protocols as referenced above. It is critical that the specialty pharmacy be able to deliver the materials required in 24 to 36 hours from the notice of award.
Small Businesses or other organizations are encouraged to respond to this notice if they are capable to meet the needs of this requirement. Written responses to this notice shall contain sufficient documentation to establish the bonafide capability and compatibility to fulfill the requirement. A complete statement of work is attached for reference.
The intended procurement will be classified under North American Industry Classification System Code 446110 Pharmacy and Drug Stores with a size standard of 500 employees.
The Government shall consider all responses received prior to the close date of this announcement. All responses must be received no later than July 28, 2013 at 1:00PM, Eastern Standard Time. Please email Brian Lind, Contract Specialist, at [email protected] with technical questions or written responses pertaining to this notice. No phone calls will be accepted.